1 unchanged sentence
Adoption, Modification and Termination of Rule 10b5-1 Plans and Certain Other Trading Arrangements.
−Removed: During the quarter ended March 31, 2025, n o n e of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (as each term is defined in Item 408 of Regulation S-K).
+Added: During the quarter ended June 30, 2025, n o n e of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (as each term is defined in Item 408 of Regulation S-K).
Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No.
2 unchanged sentences
001-37581), filed with the SEC on August 7, 2023 ).
+Added: Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No.
+Added: 001-37581), filed with the SEC on June 5, 2025).
Amended and Restated Bylaws of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No.
001-37581), filed with the SEC on June 24, 2020).
−Removed: Employment Agreement, dated as of February 26, 2025, by and between the Registrant and Neal Walker (incorporated herein by reference to Exhibit 10.21 to the Registrant’s Annual Report on Form 10-K (File No.
−Removed: 001-37581), filed with the SEC on February 27, 2025.
−Removed: Amended and Restated Sales Agreement, dated February 27, 2025, by and among the Registrant, Leerink Partners LLC and Cantor Fitzgerald & Co.
−Removed: (incorporated herein by reference to Exhibit 10.24 to the Registrant’s Annual Report on Form 10-K (File No.
−Removed: 001-37581), filed with the SEC on February 27, 2025.
−Removed: Employment Agreement, dated as of April 28, 2025, by and between the Registrant and Jesse Hall.
−Removed: Tenth Amended and Restated Non-Employee Director Compensation Policy.
+Added: Aclaris Therapeutics, Inc.
+Added: 2025 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No.
+Added: 001-37581), filed with the SEC on June 5, 2025 ).
+Added: Form of Stock Option Grant Notice and Option Agreement used in connection with the Aclaris Therapeutics, Inc.
+Added: 2025 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K (File No.
+Added: 001-37581), filed with the SEC on June 5, 2025).
+Added: Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement used in connection with the Aclaris Therapeutics, Inc.
+Added: 2025 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K (File No.
+Added: 001-37581), filed with the SEC on June 5, 2025 ).
+Added: Employment Agreement, dated as of April 28, 2025, by and between the Registrant and Jesse Hall (incorporated herein by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q (File No.
+Added: 001-37581), filed with the SEC on May 8, 2025).
+Added: Tenth Amended and Restated Non-Employee Director Compensation Policy (incorporated herein by reference to Exhibit 10.4 to the Registrant’s Quarterly Report on Form 10-Q (File No.
+Added: 001-37581), filed with the SEC on May 8, 2025).
Certification of Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act.
12 unchanged sentences
Indicates management contract or compensatory plan.
−Removed: Pursuant to Item 601(a)(5) of Regulation S-K promulgated by the SEC, certain exhibits and schedules to this agreement have been omitted.
−Removed: The Company hereby agrees to furnish supplementally to the SEC, upon its request, any or all of such omitted exhibits or schedules.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ACLARIS THERAPEUTICS, INC.
+Added: August 7, 2025
/s/ Neal Walker
1 unchanged sentence
(On behalf of the Registrant)
+Added: August 7, 2025
/s/ Kevin Balthaser
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.